Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab

Abstract: Trastuzumab is a monoclonal antibody targeting HER-2. HER-2 overexpression has been described in gallbladder cancer and in cholangiocarcinoma. This report describes the first case of a patient with HER-2 overexpressing metastatic gallbladder adenocarcinoma and responding radiographically and biochemically to trastuzumab alone.

Keywords: metastatic gallbladder adenocarcinoma, HER-2 overexpression, trastuzumab

Case report
AK is a 61-year-old woman who developed right upper quadrant pain and underwent a laparoscopic cholecystectomy on January 22, 2013. Operative findings included a “porcelain” gallbladder, an apparent liver metastasis, and peritoneal metastases. The gallbladder was removed and one liver lesion was biopsied. Pathology confirmed a poorly differentiated gallbladder adenocarcinoma and metastatic liver disease. Immunohistochemical stains were strongly positive for CK7, polyclonal CEA, and nuclear CDX-2. Based on the histology and immunostaining, the pathologist wrote “these findings are consistent with a gallbladder origin”.

On February 5, 2013, chemotherapy was initiated with cisplatinum (25 mg/m², days 1 and 8) and gemcitabine (1,000 mg/m², days 1 and 8) every 21 days. After two cycles, her CA19-9 had increased from 1,070 U/mL to 3,769 U/mL (0–35 U/mL) and a computed tomography (CT) scan of her chest/abdomen/pelvis showed “interval progression” of her metastatic liver disease (largest liver lesion now 8 × 5 cm).

Immunohistochemical staining revealed “HER-2 immunostain is strongly positive in the majority of tumor cells”. The pathologist wrote “The clinical significance of this finding in these tumors is unknown”. The pathologist noted that the staining would be the equivalent of 3+ by immunohistochemistry for HER-2 had this been a breast cancer specimen or a gastric cancer specimen.

Breast and gastric cancers are the only tumors where HER-2 3+ staining is currently defined. The definition of 3+ staining for breast cancer is “very strong, complete, circumferential, membrane staining in 10%–30% of the tumor cells”, and in gastric cancer the definition of 3+ staining is complete, basal lateral, or lateral membranous reactivity that is seen in greater than 10% of tumor cells.

On April 9, 2013, therapy was started with weekly paclitaxel (80 mg/m²) and trastuzumab (4 mg/kg loading dose followed by 2 mg/m²). Her CA19-9 improved from 4,143 U/mL on April 9, 2013 to 1,370 U/mL on May 21, 2013. A CT scan on May 20, 2013 showed “interval decrease in the size of the liver metastases”, with the
largest lesion having decreased in size from 8.5 × 5 cm to
5.4 × 3.8 cm. There were no new lesions seen. Paclitaxel
therapy was discontinued and the patient has remained on
single-agent trastuzumab weekly. By June 26, 2013, her
CA19-9 had improved to 432 U/mL and a repeat CT on
July 1, 2013 showed “interval decrease in the size of the liver
metastases”, with the largest lesion having decreased in size
from 5.4 × 3.8 cm to 2.8 × 2.1 cm. She continued to receive
trastuzumab alone, and a repeat CT scan on September 18,
2013 showed a further response of her metastatic disease
to trastuzumab alone, with the largest liver lesion having
decreased in size from 2.8 × 2.1 cm to 1.3 × 0.8 cm. Again,
there were no enlarging or new lesions.

**Discussion**

HER-2 is an ErbB tyrosine kinase family receptor. In breast
cancer, trastuzumab is approved by the US Food and
Drug Administration for use as part of adjuvant and
metastatic disease therapy in patients with tumors that
overexpress HER-2 as measured by immunohistochem-
istry (ie, 3+) or show HER-2 gene amplification by
fluorescence in situ hybridization. Trastuzumab is also
approved for use in combination with chemotherapy for
patients with HER2-overexpressing metastatic gastric
gastroesophageal cancers. Biliary cancers are relatively rare cancers and include adenocarcinomas originating in the gallbladder or bile ducts. Once metastatic, these malignancies are considered incurable. Patients randomized to receive gemcitabine and cisplatinum showed a small overall survival benefit of 11.7 months compared with 8.1 months for those receiving gemcitabine alone. This combination has consequently become a standard first-line therapy for patients with metastatic biliary cancer. The cancer in our patient progressed while she received that therapy was discontinued and the patient has remained on combination with trastuzumab, so the durability of this response remains to be seen. Ideally, a study of patients with HER-2-overexpressing biliary cancer might confirm the benefit of using trastuzumab in patients with HER-2-overexpressing biliary cancer.

**Disclosure**

The author is on the Genentech speakers bureau for products other than trastuzumab. Otherwise, the author declares no relevant conflicts of interest in this work.

**References**

1. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling
network: receptor heterodimerization in development and cancer.
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network.
monotherapy in metastatic breast cancer. Oncology. 2001;61 Suppl 2:
37–42.
4. Slamon DJ, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-
5. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combi-
nation with chemotherapy versus chemotherapy alone for treatment of
HER2-positive advanced gastric or gastro-oesophageal junction cancer
(ToGA): a phase 3, open-label, randomised controlled trial. Lancet.
2010;376(8742):687–697.
7. Aishima SI, Tagucki KI, Sugimachi K, Shimada M, Sugimachi K,
Tsuneyoshi M. c-erbB-2 and c-Met expression relates to cholangio-
carcinogenesis and progression of intrahepatic cholangiocarcinoma.
8. Ito Y, Takeda T, Sasaki Y, et al. Expression and clinical significance of
the erbB family in intrahepatic cholangiocellular carcinoma. Pathol
overexpression of c-erbB-2 (Her-2/neu) in human intrahepatic
cholangiocarcinoma as detected by fluorescence in situ hybridization,
in situ hybridization, and immunohistochemistry. J Hepatol.
prognostic significance of EGFR, VEGF and HER2 expression in
11. Law JY. Dramatic response to trastuzumab and paclitaxel in a patient
with human epidermal growth factor receptor 2-positive metastatic
Radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab